Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer
| Autor: | Kris M. Mahadeo, Dristhi Ragoonanan, Sattva S. Neelapu, Neena Kapoor, Francesco Paolo Tambaro, Partow Kebriaei, Jeffery J. Auletta, Natalie Dailey Garnes, Katayoun Rezvani, Ali Haider Ahmad, Jonathan Gill, Jeffrey Miller, David McCall, Fiorela N. Hernandez Tejada, Julie C. Fitzgerald, Marie E. Steiner, Selim Corbacioglu, Cristina Gutierrez, Rajinder P.S. Bajwa, Branko Cuglievan, Shulin Li, Rita D. Swinford, Linda Chi, Sung Won Choi, Joseph Angelo, Demetrios Petropoulos, Keri Schadler, Sangeeta Hingorani, Matteo Di Nardo, Paul L. Martin, Sajad Khazal, Elizabeth J. Shpall, Christine Duncan, Jennifer McArthur, Basirat Shoberu, Hisham Abdel-Azim, Maria E. Mireles, Priti Tewari, Courtney M. Rowan, Leslie Lehmann, William G. Wierda, Alison M. Gulbis |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
0301 basic medicine medicine.medical_specialty Adolescent Drug-Related Side Effects and Adverse Reactions medicine.medical_treatment Psychological intervention Lung injury Severity of Illness Index Article Young Adult 03 medical and health sciences Antineoplastic Agents Immunological 0302 clinical medicine Neoplasms Severity of illness medicine Humans Immunologic Factors Age of Onset Young adult Child Intensive care medicine Receptors Chimeric Antigen business.industry Age Factors Hematopoietic Stem Cell Transplantation Transfusion Reaction Cancer Immunotherapy medicine.disease Chimeric antigen receptor Clinical trial Transfusion-Related Acute Lung Injury 030104 developmental biology Oncology 030220 oncology & carcinogenesis business |
| Zdroj: | Nat Rev Clin Oncol |
| ISSN: | 1759-4782 1759-4774 |
| Popis: | Cancer immunotherapies are associated with remarkable therapeutic response rates but also with unique and severe toxicities, which potentially result in rapid deterioration in health. The number of clinical applications for novel immune effector-cell therapies, including chimeric antigen receptor (CAR)-expressing cells, and other immunotherapies, such as immune-checkpoint inhibitors, is increasing. In this Consensus Statement, members of the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network Hematopoietic Cell Transplantation-Cancer Immunotherapy (HCT-CI) Subgroup, Paediatric Diseases Working Party (PDWP) of the European Society of Blood and Marrow Transplantation (EBMT), Supportive Care Committee of the Pediatric Transplantation and Cellular Therapy Consortium (PTCTC) and MD Anderson Cancer Center CAR T Cell Therapy-Associated Toxicity (CARTOX) Program collaborated to provide updated comprehensive recommendations for the care of children, adolescents and young adults receiving cancer immunotherapies. With these recommendations, we address emerging toxicity mitigation strategies, we advocate for the characterization of baseline organ function according to age and discipline-specific criteria, we recommend early critical care assessment when indicated, with consideration of reversibility of underlying pathology (instead of organ failure scores) to guide critical care interventions, and we call for researchers, regulatory agencies and sponsors to support and facilitate early inclusion of young patients with cancer in well-designed clinical trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink